[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100220467":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":23,"responsibleParty":42,"collaborators":10,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":46,"sex":52,"minAge":53,"maxAge":10,"enrollmentInfo":54,"targetDuration":57,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":66,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":10,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Tohoku University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Non-valvular atrial fibrillation",null,"* Patients diagnosed with non-valvular atrial fibrillation\n* Patients who are treated or will be treated with rivaroxaban",[13],{"name":14,"affiliation":15,"role":16},"Hiroaki Shimokawa, MD, PhD","Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine","STUDY_CHAIR",[18],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Koji Fukuda, M.D., Ph. D","CONTACT","+81-22-717-7153","fukuda@cardio.med.tohoku.ac.jp",[24],{"facility":15,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"RECRUITING","Sendai","Miyagi","980-6574","Japan","JP",{"type":32,"coordinates":33},"Point",[34,35],140.86667,38.26667,{"lat":35,"lon":34},[38,40],{"name":39,"role":20,"phone":21,"phoneExt":10,"email":22},"Koji Fukuda, MD, PhD",{"name":14,"role":41,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":41,"investigatorFullName":14,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"MD, PhD, Department of Cardiovascular Medicine","100220467","evaluation-of-effectiveness-and-safety-of-xa-inhibitor-for-the-prevention-of-stroke-and-systemic-embolism-in-a-nationwide-cohort-of-japanese-patients-diagnosed-as-non-valvular-atrial-fibrillation-100220467",false,"NCT02147444","Evaluation of Effectiveness and Safety of Xa Inhibitor for the Prevention of Stroke And Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-valvular Atrial Fibrillation","Multi-center, Prospective, Non-interventional, Observational Cohort Study to Investigate Effectiveness and Safety of Rivaroxaban on Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Japanese Clinical Practice","EXPAND","Inclusion Criteria:\n\nPatients who meet all the criteria below\n\n* Patients aged over 20 years\n* Patients diagnosed with non-valvular atrial fibrillation\n* Patients who are treated or will be treated with rivaroxaban\n* Patients from whom written informed consent has been obtained\n\nExclusion Criteria:\n\nPatients who meet any of the criteria below\n\n* The following patients in whom rivaroxaban is contraindicated for use\n* Patients with a history of allergies to the ingredients contained in this drug\n* Patients having a hemorrhagic event (intracranial hemorrhage, gastrointestinal hemorrhage or other clinically significant hemorrhagic events)\n* Patients having liver disease complicated with coagulation disorder or those having moderate or worse liver disorder (Grade B or C in accordance with the Child-Pugh classification)\n* Patients having renal failure (creatinine clearance: \\\u003C15 mL\u002Fmin)\n* Women who are or are likely to be pregnant\n* Patients who are treated with HIV protease inhibitors (including ritonavir, atazanavir and indinavir)\n* Patients who are treated with oral or injectable formulations of azole antifungal drugs (including itraconazole, voriconazole and ketoconazole (excluding fluconazole))","ALL","20 Years",{"count":55,"type":56},7000,"ESTIMATED","2 Years","OBSERVATIONAL","The efficacy and safety of a novel oral Xa inhibitor for stroke and systemic embolism, namely rivaroxaban, in non-valvular atrial fibrillation patients are evaluated in Japanese clinical practice.",[61],"Non-valvular Atrial Fibrillation",[63,9,64,65],"Rivaroxaban","NOAC","Xa inhibitor","UNKNOWN","2014-05-21",{"date":69,"type":56},"2014-05-26",{"date":71,"type":10},"2012-11",{"name":5,"class":6},1]